<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039481</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01872</org_study_id>
    <secondary_id>ADVL0211</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <secondary_id>CDR0000069387</secondary_id>
    <nct_id>NCT00039481</nct_id>
    <nct_alias>NCT00061191</nct_alias>
  </id_info>
  <brief_title>Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Trial Of G3139 (BCL-2 Antisense, NSC# 683428, IND# 58842) Combined With Cytotoxic Chemotherapy In Relapsed Childhood Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of oblimersen plus combination chemotherapy and&#xD;
      dexrazoxane in treating children and adolescents who have relapsed or refractory solid&#xD;
      tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Oblimersen may increase the effectiveness of doxorubicin and&#xD;
      cyclophosphamide by making the tumor cells more sensitive to the drug. Chemoprotective drugs&#xD;
      such as dexrazoxane may protect normal cells from the side effects of chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the dose-limiting toxic effects and recommended phase II dose of oblimersen when&#xD;
      combined with cyclophosphamide, doxorubicin, and dexrazoxane in pediatric patients with&#xD;
      relapsed or refractory solid tumors.&#xD;
&#xD;
      II. Determine the pharmacokinetic behavior of this regimen in these patients. III. Determine,&#xD;
      preliminarily, the antitumor activity of oblimersen in these patients.&#xD;
&#xD;
      IV. Assess the biologic activity of oblimersen in mononuclear cells and tumor tissues, in&#xD;
      terms of bcl-2 and related protein expression, in these patients.&#xD;
&#xD;
      OUTLINE: This is a 2-part, multicenter, dose-escalation study.&#xD;
&#xD;
      Part A: Patients receive oblimersen IV continuously on days 1-7. Patients also receive&#xD;
      dexrazoxane IV followed by doxorubicin IV over 15 minutes followed by cyclophosphamide IV&#xD;
      over 1 hour on days 5 and 6. Filgrastim (G-CSF) is administered subcutaneously once daily&#xD;
      beginning on day 8 and continuing until blood counts recover. Treatment repeats every 21 days&#xD;
      for up to 18 courses (1 year) in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients with stable or responding disease whose shortening fraction falls below 28% by&#xD;
      echocardiogram or whose total life-time cumulative anthracycline dose exceeds 750 mg/m^2 may&#xD;
      receive additional courses of oblimersen and cyclophosphamide without doxorubicin and&#xD;
      dexrazoxane.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Part B: Patients receive oblimersen at the MTD determined in part A and escalating doses of&#xD;
      dexrazoxane, doxorubicin, and cyclophosphamide on the same treatment schedule as in part A.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of dexrazoxane, doxorubicin, and&#xD;
      cyclophosphamide until the maximum tolerated dose (MTD) is determined. The MTD is defined as&#xD;
      the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-15 patients will be accrued for this study within 1-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxic effects and recommended phase II dose, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0</measure>
    <time_frame>Up to day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pharmacokinetic behavior of this regimen</measure>
    <time_frame>Days 1 (pre-infusion), 5, 6, and 8 (end of infusion)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>Up to day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biologic activity of oblimersen in mononuclear cells and tumor tissues, in terms of B-cell lymphoma 2 (bcl-2) and related protein expression</measure>
    <time_frame>Up to day 21</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Cardiac Toxicity</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (Oblimersen sodium, cytotoxic chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>oblimersen sodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Oblimersen sodium, cytotoxic chemotherapy)</arm_group_label>
    <other_name>augmerosen</other_name>
    <other_name>G3139</other_name>
    <other_name>G3139 bcl-2 antisense oligodeoxynucleotide</other_name>
    <other_name>Genasense</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexrazoxane hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Oblimersen sodium, cytotoxic chemotherapy)</arm_group_label>
    <other_name>Cardioxane</other_name>
    <other_name>Savene</other_name>
    <other_name>Totect</other_name>
    <other_name>Zinecard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Oblimersen sodium, cytotoxic chemotherapy)</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Oblimersen sodium, cytotoxic chemotherapy)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (Oblimersen sodium, cytotoxic chemotherapy)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (Oblimersen sodium, cytotoxic chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (Oblimersen sodium, cytotoxic chemotherapy)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor at original diagnosis that has failed standard&#xD;
             therapy or for which no standard therapy exists&#xD;
&#xD;
               -  Patients must have a disease for which there is no known curative potential&#xD;
&#xD;
          -  Patients must meet the following criteria for bone marrow function:&#xD;
&#xD;
               -  Status post stem cell transplantation (SCT)&#xD;
&#xD;
               -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
               -  Platelet count at least 100,000/mm^3 (transfusion independent)&#xD;
&#xD;
               -  Hemoglobin at least 8.0 g/dL (RBC transfusions allowed)&#xD;
&#xD;
          -  No lymphomas&#xD;
&#xD;
          -  No CNS tumors or known metastatic disease to the brain or spinal cord&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100% (age 11 to 21)&#xD;
&#xD;
          -  Performance status - Lansky 50-100% (age 1 to 10)&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT no greater than 3 times ULN&#xD;
&#xD;
          -  No significant hepatic dysfunction&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min&#xD;
&#xD;
          -  Creatinine, based on age, as follows:&#xD;
&#xD;
               -  Age 1 to 5: no greater than 0.8 mg/dL&#xD;
&#xD;
               -  Age 6 to 10: no greater than 1.0 mg/dL&#xD;
&#xD;
               -  Age 11 to 15: no greater than 1.2 mg/dL&#xD;
&#xD;
               -  Age 16 to 21: no greater than 1.5 mg/dL&#xD;
&#xD;
          -  No significant renal dysfunction&#xD;
&#xD;
          -  Shortening fraction at least 28% by echocardiogram&#xD;
&#xD;
          -  Ejection fraction at least 45% by MUGA&#xD;
&#xD;
          -  No significant pulmonary dysfunction&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No serious uncontrolled infections&#xD;
&#xD;
          -  No other end-organ dysfunction that would preclude study entry&#xD;
&#xD;
          -  No other clinically significant systemic illness&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
          -  At least 1 week since prior growth factors or other biologic agents&#xD;
&#xD;
          -  At least 6 months since prior autologous SCT&#xD;
&#xD;
          -  At least 6 months since prior allogeneic bone marrow transplantation and recovered&#xD;
             with no evidence of graft-versus-host disease&#xD;
&#xD;
          -  No concurrent immunomodulating agents&#xD;
&#xD;
          -  No concurrent prophylactic growth factors during the first course of the study&#xD;
&#xD;
          -  No concurrent immunotherapy or other biologic therapy&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  No prior life-time cumulative doxorubicin dose of more than 450 mg/m^2 or equivalent&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  Concurrent chronic steroids allowed&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior localized palliative radiotherapy (small port)&#xD;
&#xD;
          -  More than 6 months since prior substantial radiotherapy to bone marrow (craniospinal&#xD;
             radiotherapy, total body irradiation, or hemi-pelvic radiotherapy)&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  Concurrent chronic medications (e.g., narcotics or antiepileptics) allowed&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent cancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Rheingold</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 16, 2013</last_update_submitted>
  <last_update_submitted_qc>January 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Razoxane</mesh_term>
    <mesh_term>Oblimersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

